Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Estudio de GS-0201 solo y en combinación en participantes con tumores sólidos avanzados

10 de noviembre de 2026 actualizado por: Gilead Sciences

Un estudio de fase 1 para evaluar la seguridad y tolerabilidad de GS-0201 como monoterapia y en combinación en adultos con tumores sólidos avanzados

The main goal of this first in human (FIH) study is to learn about the safety and dosing of GS-0201 when given alone or in combination with sacituzumab govitecan (SG) in participants with advanced solid tumors.

The primary objectives of this study are to:

  • To assess the safety and tolerability of GS-0201 as monotherapy and in combination with SG in participants with selected advanced solid tumors
  • To identify the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of GS-0201 as monotherapy and the MTD and/or the RP2D and dosing schedule of GS-0201 in combination with SG in participants with selected advanced solid tumors

Descripción general del estudio

Estado

Reclutamiento

Tipo de estudio

Intervencionista

Inscripción (Estimado)

278

Fase

  • Fase 1

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

      • Gangnam-Gu, Corea del Sur, 06351
        • Reclutamiento
        • Samsung Medical Center
      • Goyang-si Gyeonggi-do, Corea del Sur, 10408
        • Reclutamiento
        • National Cancer Center - Korea
      • Seoul, Corea del Sur, 05505
        • Reclutamiento
        • Asan Medical Center
      • Seoul, Corea del Sur, 03722
        • Reclutamiento
        • Yonsei University Severance Hospital
      • Seoul, Corea del Sur, 03080
        • Reclutamiento
        • Samsung Medical Center
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02459
        • Reclutamiento
        • Dana-Farber Cancer Institute
    • New York
      • New York, New York, Estados Unidos, 10065
        • Reclutamiento
        • Memorial Sloan Kettering Cancer Center
    • Texas
      • Austin, Texas, Estados Unidos, 78758
        • Reclutamiento
        • NEXT Austin
      • Houston, Texas, Estados Unidos, 77030
        • Reclutamiento
        • The University of Texas MD Anderson Cancer Center
      • Irving, Texas, Estados Unidos, 75039
        • Reclutamiento
        • NEXT Dallas
      • Haifa, Israel, 31096
        • Reclutamiento
        • Rambam Health Care Campus
      • Jerusalem, Israel, 9112001
        • Reclutamiento
        • Hadassah Medical Center
      • Tel Aviv, Israel, 6423906
        • Reclutamiento
        • Tel Aviv Sourasky Medical Center
      • Tel HaShomer, Israel, 52621
        • Reclutamiento
        • Chaim Sheba Medical Center

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Able to understand and give written informed consent.

  • Assigned female or male at birth, 18 years of age or older, and meet the age of majority/adulthood per local regulations.

  • Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1.

  • Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria by investigator assessment.

  • Organ function requirements:

    • Adequate hematologic function
    • Adequate hepatic function
    • Creatinine clearance
    • Coagulation
  • Tissue requirement:

    • Parts A, B, C, and D:

      • Pre-treatment tumor tissue is required.
    • Parts A and C backfill biopsy cohorts:

      • Individuals must agree to fresh pre- and on-treatment biopsies.
  • Individuals assigned male at birth and individuals assigned female at birth and of childbearing potential who engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception

  • Willing and able to comply with the requirements and restrictions in this protocol

  • Part A (GS-0201 Monotherapy Dose Escalation) Inclusion Criteria:

    • Histologically/cytologically confirmed progressive/advanced solid tumors with selected molecular lesions.
    • Individuals must have received, been intolerant to, or been ineligible for all treatment known to confer clinical benefit or have a contraindication to receive the therapy
  • Part B (Dose Expansion) Inclusion Criteria:

    • Disease documented as:

    • Cohort B1:

      • Histologically or cytologically confirmed progressive/advanced selected solid tumor diagnoses harboring defined molecular lesions
      • Participants may potentially be required to forgo treatment with approved agent(s) to be able to participate in the study
    • Cohort B2:

      • Histologically or cytologically confirmed progressive/advanced solid tumor diagnoses harboring defined molecular lesions not included in Cohort B1
  • Part C (Dose Escalation) Inclusion Criteria:

    • Histologically or cytologically confirmed unresectable locally advanced/metastatic selected solid tumors
  • Part D (Dose Expansion) Inclusion Criteria:

    • Disease documented as:

    • Cohort D1:

      • Histologically or cytologically confirmed unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC)
    • Cohort D2:

      • Recurrent/persistent endometrial cancer

Exclusion Criteria:

  • Pregnant or lactating females

  • Known hypersensitivity to any of the study drugs, its metabolites, or formulation excipients

  • Requirement for ongoing therapy with or use of any prohibited medications described in the protocol

  • Individuals with myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or with findings suggestive of MDS/AML

  • Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of GS-0201

  • The therapies listed below within the specified timeframe:

    • Major surgery (excluding minor procedures, eg, placement of vascular access, gastrointestinal/biliary stent, biopsy) < 4 weeks prior to planned Cycle 1 Day 1
    • Immunotherapy or biologic therapy < 21 days prior to planned Cycle 1 Day 1
    • Chemotherapy < 14 days prior to planned Cycle 1 Day 1, or < 42 days for mitomycin or nitrosoureas
    • Targeted small molecule therapy < 14 days prior to planned Cycle 1 Day 1
    • Receipt of experimental therapy within 21 days or 5 experimental treatment half-lives (whichever is longer) prior to planned Cycle 1 Day 1
    • Hormonal or other adjunctive therapy for cancers other than the cancer under evaluation in this study that started < 14 days prior to planned Cycle 1 Day 1 are not permitted. Hormonal therapy, bisphosphonates, somatostatin analogues, and leuprolide are permitted if started ≥ 14 days prior to planned Cycle 1 Day 1
    • Radiotherapy within 2 weeks prior to planned Cycle 1 Day 1 and the radiation is not administered to a target lesion
    • Any prior allogeneic tissue/solid organ transplantation, including allogeneic hematopoietic stem cell transplantation. Individuals with a history of autologous hematopoietic stem cell transplantation are also excluded
  • Have not recovered (ie, Grade 1 or lower) from AEs due to a previously administered agent

  • Prior treatment with approved or experimental prohibited agents as detailed in the protocol.

  • Diagnosis of immunodeficiency, either primary or acquired, or requires systemic corticosteroids (> 10 mg of prednisone daily, or equivalent). However, replacement doses, topical, ophthalmologic, and inhalational steroids are permitted

  • Have an active second malignancy

  • Have known active central nervous system (CNS) metastases

  • Individuals with carcinomatous meningitis or primary CNS tumors are excluded regardless of clinical stability

  • Meet any of the following criteria for cardiac disease:

    • Myocardial infarction or unstable angina pectoris within 6 months of enrollment
    • History of serious ventricular arrhythmia (ie, ventricular tachycardia or ventricular fibrillation), high-grade atrioventricular block, or other cardiac arrhythmias requiring antiarrhythmic medications (except for atrial fibrillation that is well controlled with antiarrhythmic medication)
    • QT interval > 470 msec
    • New York Heart Association Class III or greater congestive heart failure or known left ventricular ejection fraction less than 40%
  • Meet any of the following infectious criteria:

    • Have active serious infection requiring antimicrobials
    • Have active hepatitis B virus (HBV) or hepatitis C virus (HCV), or HIV. In individuals with a history of HBV or HCV, individuals with detectable viral loads will be excluded
    • Individuals who test positive for hepatitis B surface antigen. Individuals who test positive for hepatitis B core antibody are eligible with a negative HBV DNA by quantitative Polymerase chain reaction (PCR)
    • Individuals who test positive for HCV antibody. Individuals who test positive for HCV antibody are eligible with a negative HCV RNA by quantitative PCR
    • Individuals who test positive for HIV antibody
  • History of pneumonitis requiring treatment with corticosteroids, interstitial lung disease, or radiation pneumonitis requiring steroids

  • Symptomatic ascites or pleural effusion

  • Have other concurrent medical or psychiatric conditions that, in the investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations

  • Any medical condition that, in the investigator's or sponsor's opinion, poses an undue risk to the individuals participation in the study

  • Use of any live vaccines against infectious diseases within 4 weeks (28 days) of initiation of study drug(s) (inactivated, viral vector vaccines, and messenger RNA (mRNA) vaccines are allowed; seasonal vaccines should be up to date prior to planned Cycle 1 Day 1)

  • Parts C (Dose Escalation) and D (Dose Expansion): Combination Cohorts:

    • Individuals with active chronic inflammatory bowel disease (ulcerative colitis, Crohn disease) and individuals with a history of bowel obstruction or gastrointestinal perforation within 6 months prior to planned Cycle 1 Day 1
    • Individuals who previously received topoisomerase 1 inhibitors or antibody-drug conjugates containing a topoisomerase 1 inhibitor
    • Known severe intolerance or life-threatening hypersensitivity reactions to humanized monoclonal antibodies or intravenous (IV) immunoglobulin preparations; any history of anaphylaxis; history of human anti-human antibody response

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: No aleatorizado
  • Modelo Intervencionista: Asignación Secuencial
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Part A: GS-0201 Monotherapy Dose Escalation

Participants will receive escalating doses of GS-0201 monotherapy, until disease progression, or until the participant meets other study drug discontinuation criteria as specified in protocol or up to 105 weeks, whichever occurs first.

Pill administered orally

Experimental: Part B: Cohort B1: GS-0201 Monotherapy Dose Expansion

Participants with selected breast cancer indication will receive GS-0201 monotherapy at the recommended dose for expansion.

Pill administered orally

Experimental: Part B: Cohort B2: GS-0201 Monotherapy Dose Expansion

Participants with selected indications not included in cohort B1 will receive GS-0201 monotherapy at the recommended dose for expansion.

Pill administered orally

Experimental: Part C: Dose Escalation: GS-0201 + Sacituzumab Govitecan (SG)

Participants will receive escalating doses of GS-0201 in combination with SG, until disease progression, or until the participant meets other study drug discontinuation criteria as specified in protocol or up to 105 weeks, whichever occurs first.

Pill administered orally

Administered intravenously

Otros nombres:
  • IMMU-132
  • GS-0132
  • Trodelvy™
Experimental: Part D: Cohort D1: Dose Expansion: GS-0201 + SG

Participants with confirmed unresectable locally advanced or metastatic triple negative breast cancer (mTNBC) will receive GS-0201 at the recommended Phase 2 dose (RP2D) in combination with SG.

Pill administered orally

Administered intravenously

Otros nombres:
  • IMMU-132
  • GS-0132
  • Trodelvy™
Experimental: Part D: Cohort D2: Dose Expansion: GS-0201 + SG

Participants with recurrent/persistent endometrial cancer will receive GS-0201 at the recommended Phase 2 dose (RP2D) in combination with SG.

Pill administered orally

Administered intravenously

Otros nombres:
  • IMMU-132
  • GS-0132
  • Trodelvy™

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
El porcentaje de participantes con eventos adversos (EA) y eventos adversos graves (AAG)
Periodo de tiempo: Primera dosis hasta 30 días después de la última dosis (hasta aproximadamente 109 semanas).
Primera dosis hasta 30 días después de la última dosis (hasta aproximadamente 109 semanas).
La incidencia de anomalías de laboratorio
Periodo de tiempo: Primera dosis hasta 30 días después de la última dosis (hasta aproximadamente 109 semanas).
Primera dosis hasta 30 días después de la última dosis (hasta aproximadamente 109 semanas).
The Number of Participants with Dose Limiting Toxicities (DLTs) During Dose Escalation
Periodo de tiempo: First dose up to 30 days post last dose (Up to approximately 109 weeks).

DLTs are defined as any of the following treatment-emergent adverse events (AEs) regardless of attribution (graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0), unless clearly related to an underlying disease or extraneous causes, with onset within the DLT-evaluation period for the corresponding dose.

First dose up to 30 days post last dose (Up to approximately 109 weeks).

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Concentraciones plasmáticas GS-0201
Periodo de tiempo: Predosis y posdosis hasta el final del tratamiento (hasta 105 semanas)
Predosis y posdosis hasta el final del tratamiento (hasta 105 semanas)
Concentraciones séricas de sacituzumab govitecan (SG) (partes C y D únicamente)
Periodo de tiempo: Predosis y posdosis hasta el final del tratamiento (hasta 105 semanas)
Predosis y posdosis hasta el final del tratamiento (hasta 105 semanas)
Pharmacokinetic (PK) Parameter: Area Under the Concentration (AUC)0-24 of GS-0201
Periodo de tiempo: Predose and postdose up to end of treatment (up to 105 weeks)

AUC0-24 is defined as the concentration of drug over time between time 0 and time 24 hours.

Predose and postdose up to end of treatment (up to 105 weeks)
PK Parameter: Cmax of GS-0201
Periodo de tiempo: Predose and postdose up to end of treatment (up to 105 weeks)

Cmax is defined as the maximum observed drug concentration.

Predose and postdose up to end of treatment (up to 105 weeks)
PK Parameter: Tmax of GS-0201
Periodo de tiempo: Predose and postdose up to end of treatment (up to 105 weeks)

Tmax is defined as the time to maximum observed concentration.

Predose and postdose up to end of treatment (up to 105 weeks)
PK Parameter: AUC0-168 of SG (Parts C and D only)
Periodo de tiempo: Predose and postdose up to end of treatment (up to 105 weeks)

AUC0-168 is defined as the concentration of drug over time between time 0 and time 168 hours.

Predose and postdose up to end of treatment (up to 105 weeks)
PK Parameter: Cmax of SG (Parts C and D only)
Periodo de tiempo: Predose and postdose up to end of treatment (up to 105 weeks)

Cmax is defined as the maximum observed drug concentration.

Predose and postdose up to end of treatment (up to 105 weeks)
PK Parameter: Tmax of SG (Parts C and D only)
Periodo de tiempo: Predose and postdose up to end of treatment (up to 105 weeks)

Tmax is defined as the time to maximum observed concentration.

Predose and postdose up to end of treatment (up to 105 weeks)

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Director de estudio: Gilead Study Director, Gilead Sciences

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

9 de enero de 2024

Finalización primaria (Estimado)

1 de septiembre de 2028

Finalización del estudio (Estimado)

1 de septiembre de 2028

Fechas de registro del estudio

Enviado por primera vez

4 de diciembre de 2023

Primero enviado que cumplió con los criterios de control de calidad

4 de diciembre de 2023

Publicado por primera vez (Actual)

12 de diciembre de 2023

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

12 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

10 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Términos MeSH relevantes adicionales

Otros números de identificación del estudio

  • GS-US-686-6854

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir